查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1250772

到 2028 年的亨廷顿病治疗市场预测——按疗法（疾病修饰疗法、对症治疗）、药剂、最终用户和地区进行的全球分析

Huntington's Disease Treatment Market Forecasts to 2028 - Global Analysis By Treatment (Disease-modifying therapies and Symptomatic treatment), Drug, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2022 年亨廷顿病治疗的全球市场规模将达到 85 亿美元，预计到 2028 年将达到 187 亿美元，预测期内增长 14.1%。预计将以 CAGR 增长。

亨廷顿舞蹈症是一种罕见的遗传性疾病，会导致大脑神经细胞进行性破坏，主要影响运动、情绪和认知能力。 在这种疾病中，大脑中的神经细胞发生故障并形成称为神经原纤维缠结的蛋白质团块，影响运动、思维、推理和情绪。 它会导致不受控制的运动和肌肉痉挛（霍乱）、语言模式改变、抑郁、焦虑和性格改变。

根据美国亨廷顿病协会 (HDSA) 的数据，2021 年将有大约 41,000 名有症状的美国人，超过 200,000 人有遗传该病的风险。

市场动态

司机：

亨廷顿病的发病率增加

全球范围内亨廷顿舞蹈病患病率的上升是推动市场增长的主要因素之一。 该程序经常用于停止不受控制的抽搐和跛行并改善生活质量。 此外，越来越多地采用临床试验、强大的药物类型管道以及改进的医疗程序和疗法预计将推动市场增长。

约束

缺乏批准的药物和严格的监管政策

目前，只有两种药物被批准用于治疗与这种疾病相关的角膜炎，而且这些药物只能控制和抑制症状，不能治癒疾病。 世界各地的公司要想批准药品，就必须扫清严格的监管障碍。 此类监管限制可能会影响市场进入者的口味，导致预测期内市场增长放缓。

机会

激活研发

由于缺乏有效的治疗方法和药物，亨廷顿病的治疗方法是一个广阔的研究和开发领域。 预计这将在预测期内显着促进市场增长。 此外，据推测，政府为促进新药开发所做的努力也有望成为支持市场增长的因素之一。

威胁

药物获取困难

由于严格的政策法规，许可药品的数量有限。 预计世界许多地区对这种疾病缺乏了解将限制市场扩张。 寻找治疗这种疾病的药物一直是一项重大挑战，许多药物未能证明疗效或与显着毒性有关。 预计这将阻碍市场增长。

COVID-19 的影响

预计 COVID-19 的爆发将对亨廷顿氏病治疗的市场规模产生不利影响。 世界各地的大量诊所和医院正在重组以容纳更多 COVID-19 患者。 患者人数的激增有时会减慢非必要任务的执行速度。 由于医疗保健所需物资的生产和交付受阻，它已经停止。 无法获得医疗保健、医疗机构人员不足以及与 COVID-19 相关的住院率上升也是影响市场的其他变量。

在预测期内，疾病缓解疗法领域预计将成为最大的领域

由于疾病缓解疗法的研究和开发不断增加，疾病缓解疗法领域预计将实现有利增长。 静脉内或口服给予的疾病缓解疗法可以减轻当前症状或减缓进展。 疾病改善疗法可以改善与这种疾病相关的问题，例如精神障碍和抑郁症，但尚未显示可以改变患者死亡率。

抗抑郁药细分市场有望在预测期内实现最高复合年增长率

预计抗抑郁药在预测期内将以最快的复合年增长率增长，因为它们旨在恢復精神稳定性。 抗抑郁药是改善临床抑郁症、听力损失、社交焦虑、焦虑和其他症状的处方药。 抗抑郁药治疗主要集中在缓解严重抑郁症的症状上。 这些是该领域增长的驱动力。

市场份额最高的地区

由于这种疾病的患病率相对较低，预计亚太地区在预测期内将占据最大的市场份额。 然而，在预测期内，这些地区改进的报销政策以及患者对可用治疗的认识提高，预计将有助于增长前景。

复合年增长率最高的地区：

由于产品渗透率不断提高，预计北美在预测期内的复合年增长率最高。 公众对该疾病的认识很高，许多公共和私人组织的研究资金和支持正在促进对该疾病的研究。 随着各国政府加紧努力改善其人口的健康，预计该地区的市场将会增长。

主要市场参与者

亨廷顿氏病治疗市场的主要参与者包括Novartis AG、Teva Pharmaceutical Industries Ltd.、Dr. Reddy's Laboratories Ltd.、Sun Pharmaceutical Industries, Inc.、Lupin、Hetero、Hikma Pharmaceuticals PLC、Bausch Health Companies Inc.、 Alterity Therapeutics、H. Lundbeck A/S、Neurocrine Biosciences, Inc.、Annexon Biosciences、PTC Therapeutics、Prilenia Therapeutics、Amneal Pharmaceuticals LLC.、SOM BIOTECH、Vertex Pharmaceuticals Incorporated。

主要发展：

2021 年 12 月，Novartis AG 获得了 FDA 对 Branaplam 治疗亨廷顿舞蹈病的快速通道指定。 Branaplam 是一种 mRNA 剪接调节剂，其靶向 HTT 蛋白，该蛋白负责引起导致亨廷顿舞蹈病的神经元变性。

2021 年 10 月，Teva Pharmaceutical Industries Limited 获得了在巴西治疗与亨廷顿舞蹈症相关的角膜炎和迟发性运动障碍的上市许可。

这份报告提供了什么

  • 区域和国家级细分市场的市场份额评估
  • 向新进入者提出战略建议
  • 2020、2021、2022、2025 和 2028 年的综合市场数据
  • 市场驱动因素（市场趋势、制约因素、机遇、威胁、挑战、投资机会/建议等）
  • 根据市场预测在关键业务领域提出战略建议
  • 竞争格局和趋势
  • 公司简介，包括详细的战略、财务状况和近期发展
  • 供应链趋势反映了最新的技术进步。

提供免费定制

购买此报告的客户将免费获得以下定制之一。

  • 公司简介
    • 对其他市场参与者（最多 3 个）进行全面分析
    • 主要参与者的 SWOT 分析（最多 3 人）
  • 区域细分
    • 应客户要求提供主要国家/地区的市场估算、预测和復合年增长率（注意：通过可行性检查）
  • 竞争基准
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 概览
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究信息来源
    • 二手研究资源
    • 假设

第三章市场趋势分析

  • 司机
  • 约束因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第 5 章全球亨廷顿病治疗市场：按治疗分类

  • 疾病缓解疗法
  • 对症治疗

第 6 章全球亨廷顿病治疗市场：按代理

  • 抗抑郁药
  • 抗精神病药
  • 镇静剂
  • 丁苯那秦
  • 其他药物

第 7 章。全球亨廷顿病治疗市场：按最终用户分类

  • 医务室
  • 医院
  • 零售药房
  • 在线药店
  • 其他最终用户

第 8 章。全球亨廷顿病治疗市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东地区

第九章主要进展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章公司简介

  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries, Inc.
  • Lupin
  • Hetero
  • Hikma Pharmaceuticals PLC
  • Bausch Health Companies Inc.
  • Alterity Therapeutics
  • H. Lundbeck A/S
  • Neurocrine Biosciences, Inc.
  • Annexon Biosciences
  • PTC Therapeutics
  • Prilenia Therapeutics
  • Amneal Pharmaceuticals LLC.
  • SOM BIOTECH
  • Vertex Pharmaceuticals Incorporated
Product Code: SMRC22649

According to Stratistics MRC, the Global Huntington's Disease Treatment Market is accounted for $8.5 billion in 2022 and is expected to reach $18.7 billion by 2028 growing at a CAGR of 14.1% during the forecast period. Huntington's disease is a rare inherited disease that causes progressive breakdown of nerve cells in the brain, mainly affecting physical movements, emotions and cognitive abilities. It is a condition in which the nerve cells of the brain malfunction and create clumps of a protein called neurofibrillary tangles that affect movement, thinking, reasoning, moods, and more. It can cause uncontrolled movements or muscle twitches (chorea), changes in speech patterns, depression, anxiety, and personality changes.

According to the Huntington's disease Society of America (HDSA), there were approximately 41,000 symptomatic Americans in 2021, with over 200,000 individuals at risk of inheriting the disease.

Market Dynamics:

Driver:

The rising incidence of Huntington's disease

The rising incidence of Huntington's disease across the globe is one of the primary factors driving the market growth. The procedure is frequently used to stop uncontrollable jerking and writhing motion, which enhances quality of life. In addition, clinical trials, strong drug type pipeline and growing adoption of improved medical treatments and therapies are expected to fuel the market growth.

Restraint:

Lack of approved drugs and stringent regulatory policies

Currently, there are only two drugs approved for the treatment of chorea associated with this condition and these drugs can only manage or control the symptoms but cannot cure the disease. Companies across the globe need to clear strict regulatory hurdles for the approval of drugs. Such regulatory limits may impact market participants' preferences, resulting in slower market growth during the projection period.

Opportunity:

Growing research and development activities

There is a vast area of research and development for Huntington's disease treatment approaches because there is no effective treatment or medication. This is expected to significantly boost market growth during the forecast period. Moreover, the promising government initiatives that promote the development of new drugs are estimated to be another factor supporting the market growth.

Threat:

Limited availability of drugs

The number of licensed pharmaceuticals is limited due to tight policies and restrictions. It is anticipated that the market's expansion will be constrained by the lack of knowledge about this illness in many regions of the world. Many medications have failed to show efficacy or have been linked to significant toxicity, which has presented significant challenges for the discovery of drugs to treat the disease. This is expected to hamper the market growth.

Covid-19 Impact

The COVID-19 outbreak is projected to have a detrimental effect on the size of the market for treating Huntington's disease. To accommodate more patients with COVID-19, a sizable number of clinics and hospitals around the world underwent restructuring. Because of the sharp increase in patients, non-essential operations could be delayed. Production and delivery of supplies for healthcare were halted as a result of the lockdown. Lack of access to healthcare, a staffing deficit in the medical field, and an increase in COVID-19-related hospitalisation are some additional variables that have an impact on the market.

The disease-modifying therapies segment is expected to be the largest during the forecast period

The disease-modifying therapies segment is estimated to have a lucrative growth, due to an increase in disease-modifying therapy R&D. They can be administered intravenously or orally to lessen current symptoms or slow their progression. Disease-modifying therapies can help with problems like psychological illnesses and depression linked to this condition, but they have not been found to change patient mortality rates.

The antidepressants segment is expected to have the highest CAGR during the forecast period

The antidepressants segment is anticipated to witness the fastest CAGR growth during the forecast period, due to they are intended to restore the mental stability. Antidepressants are prescription medications that can help with symptoms of clinical depression, dysthymia, social anxiety, anxiety, and other conditions. Treatment with antidepressants focuses primarily on reducing the symptoms of severe depression. These are driving the segment growth.

Region with Largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the comparatively lower prevalence rate of this condition amongst the population. However, increasing awareness among the patient population toward available treatment along with improving reimbursement policies in these regions during the forecast period will contribute to their growth prospects.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increasing product penetration. A high level of public awareness about the condition, as well as growing support from numerous public and private organisations through research funding, to expedite the study of this disease. As governments take more initiatives to improve the health status of the populations, the market in the region is expected to grow.

Key Players in the market

Some of the key players profiled in the Huntington's Disease Treatment Market include Novartis AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries, Inc., Lupin, Hetero, Hikma Pharmaceuticals PLC, Bausch Health Companies Inc., Alterity Therapeutics, H. Lundbeck A/S, Neurocrine Biosciences, Inc., Annexon Biosciences, PTC Therapeutics, Prilenia Therapeutics, Amneal Pharmaceuticals LLC., SOM BIOTECH and Vertex Pharmaceuticals Incorporated.

Key Developments:

In December 2021, Novartis AG received Fast Track designation for Branaplam from the FDA for Huntington's disease treatment. Branaplam is an mRNA splicing modulator that targets the HTT protein responsible for causing the degeneration of nerve cells leading to Huntington's disease.

In October 2021, Teva Pharmaceutical Industries Ltd. Received marketing approval for the treatment of chorea associated with Huntington's disease treatment and for the treatment of tardive dyskinesia in Brazil.

Treatments Covered:

  • Disease-modifying therapies
  • Symptomatic treatment

Drugs Covered:

  • Antidepressants
  • Antipsychotic Drugs
  • Tranquilizers
  • Tetrabenazine
  • Other Drugs

End Users Covered:

  • Clinics
  • Hospital
  • Retail Pharmacies
  • Online Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Huntington's Disease Treatment Market, By Treatment

  • 5.1 Introduction
  • 5.2 Disease-modifying therapies
  • 5.3 Symptomatic treatment

6 Global Huntington's Disease Treatment Market, By Drug

  • 6.1 Introduction
  • 6.2 Antidepressants
  • 6.3 Antipsychotic Drugs
  • 6.4 Tranquilizers
  • 6.5 Tetrabenazine
  • 6.6 Other Drugs

7 Global Huntington's Disease Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Clinics
  • 7.3 Hospital
  • 7.4 Retail Pharmacies
  • 7.5 Online Pharmacies
  • 7.6 Other End Users

8 Global Huntington's Disease Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Novartis AG
  • 10.2 Teva Pharmaceutical Industries Ltd.
  • 10.3 Dr. Reddy's Laboratories Ltd.
  • 10.4 Sun Pharmaceutical Industries, Inc.
  • 10.5 Lupin
  • 10.6 Hetero
  • 10.7 Hikma Pharmaceuticals PLC
  • 10.8 Bausch Health Companies Inc.
  • 10.9 Alterity Therapeutics
  • 10.10 H. Lundbeck A/S
  • 10.11 Neurocrine Biosciences, Inc.
  • 10.12 Annexon Biosciences
  • 10.13 PTC Therapeutics
  • 10.14 Prilenia Therapeutics
  • 10.15 Amneal Pharmaceuticals LLC.
  • 10.16 SOM BIOTECH
  • 10.17 Vertex Pharmaceuticals Incorporated

List of Tables

  • Table 1 Global Huntington's Disease Treatment Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 3 Global Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 4 Global Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 5 Global Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 6 Global Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 7 Global Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 8 Global Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 9 Global Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 10 Global Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 11 Global Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 12 Global Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 13 Global Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 14 Global Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 15 Global Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 16 Global Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 17 North America Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 18 North America Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 19 North America Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 20 North America Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 21 North America Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 22 North America Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 23 North America Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 24 North America Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 25 North America Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 26 North America Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 27 North America Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 28 North America Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 29 North America Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 30 North America Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 31 North America Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 32 North America Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 33 Europe Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 34 Europe Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 35 Europe Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 36 Europe Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 37 Europe Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 38 Europe Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 39 Europe Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 40 Europe Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 41 Europe Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 42 Europe Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 43 Europe Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 44 Europe Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 45 Europe Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 46 Europe Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 47 Europe Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 48 Europe Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 49 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 50 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 51 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 52 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 53 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 54 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 55 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 56 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 57 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 58 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 59 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 60 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 61 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 62 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 63 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 64 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 65 South America Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 66 South America Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 67 South America Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 68 South America Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 69 South America Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 70 South America Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 71 South America Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 72 South America Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 73 South America Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 74 South America Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 75 South America Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 76 South America Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 77 South America Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 78 South America Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 79 South America Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 80 South America Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
  • Table 81 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
  • Table 82 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
  • Table 83 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
  • Table 84 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
  • Table 85 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
  • Table 86 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
  • Table 87 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
  • Table 88 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
  • Table 89 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
  • Table 90 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
  • Table 91 Middle East & Africa Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
  • Table 92 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
  • Table 93 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
  • Table 94 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 95 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 96 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)